(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 73.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Alumis's revenue in 2026 is $22,121,000.On average, 12 Wall Street analysts forecast ALMS's revenue for 2026 to be $616,338,651, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $1,644,196,097. On average, 10 Wall Street analysts forecast ALMS's revenue for 2027 to be $3,201,119,310, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $7,683,876,428.
In 2028, ALMS is forecast to generate $14,186,019,534 in revenue, with the lowest revenue forecast at $5,964,412,687 and the highest revenue forecast at $21,418,394,494.